Schonfeld Strategic Advisors LLC Has $291,000 Stock Position in Penumbra, Inc. (NYSE:PEN)

Schonfeld Strategic Advisors LLC lowered its position in Penumbra, Inc. (NYSE:PEN - Free Report) by 60.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,226 shares of the company's stock after selling 1,901 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Penumbra were worth $291,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in PEN. Barclays PLC increased its position in shares of Penumbra by 16.5% in the third quarter. Barclays PLC now owns 18,025 shares of the company's stock valued at $3,502,000 after buying an additional 2,559 shares in the last quarter. Pallas Capital Advisors LLC boosted its stake in Penumbra by 3.8% in the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after buying an additional 41 shares during the last quarter. Park Avenue Securities LLC boosted its stake in Penumbra by 18.6% in the 4th quarter. Park Avenue Securities LLC now owns 1,665 shares of the company's stock worth $395,000 after buying an additional 261 shares during the last quarter. Diversify Wealth Management LLC boosted its stake in Penumbra by 36.3% in the 4th quarter. Diversify Wealth Management LLC now owns 1,645 shares of the company's stock worth $412,000 after buying an additional 438 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after buying an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company's stock.

Insiders Place Their Bets

In other news, Director Thomas Wilder sold 360 shares of the company's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the sale, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. This represents a 7.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Lambert Shiu sold 501 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $282.88, for a total value of $141,722.88. Following the sale, the chief accounting officer now owns 32,969 shares of the company's stock, valued at approximately $9,326,270.72. This trade represents a 1.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,696 shares of company stock valued at $50,207,745 in the last three months. Insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PEN. Piper Sandler reissued an "overweight" rating and issued a $330.00 price target (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Wells Fargo & Company lifted their price objective on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. UBS Group reaffirmed a "buy" rating and issued a $330.00 price objective (up from $320.00) on shares of Penumbra in a research note on Thursday, April 24th. Morgan Stanley lifted their price objective on Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 19th. Finally, StockNews.com upgraded Penumbra from a "hold" rating to a "buy" rating in a report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Penumbra Stock Up 2.1%

PEN stock traded up $5.78 during mid-day trading on Friday, hitting $281.10. The stock had a trading volume of 711,568 shares, compared to its average volume of 440,534. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00. The company has a fifty day moving average of $279.37 and a 200 day moving average of $263.71. The stock has a market capitalization of $10.89 billion, a price-to-earnings ratio of 826.76, a PEG ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. During the same period in the prior year, the firm posted $0.41 EPS. The business's revenue was up 16.3% compared to the same quarter last year. On average, equities analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.